Chonluten

Also known as: EDG, Glu-Asp-Gly, T-34

Evidence: Preclinical

PeptideLab is an educational platform for learning about peptides. The information here is for educational and research purposes only. It is not medical advice, diagnosis, or treatment, and PeptideLab does not claim to diagnose, treat, cure, or prevent any disease or health condition. Many peptides discussed have not been approved for human use by the FDA or other regulatory bodies. Consult a qualified healthcare professional before making any health-related decision.

Overview

Khavinson-series synthetic tripeptide (EDG) assigned to bronchial tissue; in vitro it suppressed LPS-induced TNF release by human monocytes. No controlled human trial.

Chonluten is a synthetic tripeptide (EDG, Glu-Asp-Gly) from the St. Petersburg Institute of Bioregulation and Gerontology, assigned to bronchial tissue and also listed as a gastroprotector (Khavinson 2022). The clearest data come from an Italian collaboration: in human THP-1 monocytes it inhibited LPS-induced TNF production and reduced adhesion to activated endothelium (Avolio 2022). A peptide coded T-34, which the group's later reviews identify as EDG, normalized antioxidant and anti-inflammatory protein synthesis in a gastric ulcer model (Khavinson 2012). A 2020 review from the developer says oral EDG helped COPD and chronic bronchitis, but cites only the ulcer paper for it (Khavinson 2020). No controlled human trial has been published.

Benefits

Lower LPS-induced TNF and IL-6 release and less endothelial adhesion by monocytes (in vitro), antioxidant and anti-inflammatory protein normalization in a gastric ulcer model (animal, peptide coded T-34)

Dosing reference

Research dose: 200 to 1000 mcg daily: vendor/community range, no published human dose
Range: 200 to 1000 mcg, 1x daily

Sold as oral capsules and as lyophilized powder for injection. No published abstract states a dose in any species. Community protocols run 10 to 20 day courses two or three times a year; no study compared schedules.

Mechanism

Proposed. In THP-1 monocytes the peptide increased tyrosine phosphorylation of mitogen-activated kinases, inhibited LPS-induced TNF and IL-6, and reduced monocyte adhesion to LPS-activated endothelial cells, which the authors describe as TNF tolerance (Avolio 2022). The developer's reviews attribute regulation of c-Fos, HSP70, SOD, COX-2 and TNF-alpha genes to EDG (Khavinson 2020). Docking ranks EDG among the strongest ligands of LAT1, LAT2 and PEPT1 (Khavinson 2022). The old claim of action on type I and II alveolar cells has no published source.

Evidence

Preclinical: animal or in vitro data only

Inhibited LPS-induced TNF production by human THP-1 monocytes and reduced their adhesion to activated endothelium (Avolio et al., 2022)
Peptide T-34, later identified by the group as EDG, normalized antioxidant and anti-inflammatory protein synthesis in a gastric ulcer model (Khavinson et al., 2012)
Docking ranks EDG among the best ligands of the LAT1, LAT2 and PEPT1 transporters (Khavinson et al., 2022)
Human-trial status: no controlled human trial published; a 2020 review from the developer describes oral use in COPD and asthmatic bronchitis without a clinical citation (Khavinson et al., 2020)

References

Side effects

No controlled safety study has been published in any species, and the animal and cell studies, almost all from the developing institute, were not designed to detect harm. Commonly reported (anecdotal): injection-site irritation with injectable forms; oral capsules draw few complaints.

Storage

Storage: Room temperature
Lyophilized: 24+ months

Pharmacology

Half-life: No published pharmacokinetic data in any species
Bioavailability: Not measured in any species. Docking predicts transport by LAT1, LAT2 and PEPT1 (Khavinson 2022)
Molecular weight: 319.27 Da
Sequence: EDG (Glu-Asp-Gly)